Evidence mapPaperPMID 29291395Full record

ArticleJournal of molecular and cellular cardiology2018

ErbB2 promotes endothelial phenotype of human left ventricular epicardial highly proliferative cells (eHiPC).

Sergey Ryzhov, Michael P Robich, Daniel J Roberts, Amanda J Favreau-Lessard, Sarah M Peterson, Edward Jachimowicz, Rutwik Rath, Calvin P H Vary, Reed Quinn, Robert S Kramer and 1 more

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in Journal of molecular and cellular cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02820233 (Isolation and Characterization of ERBB Expressing Human Heart Progenitor Cells), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02820233 recruitingnot on this map

Isolation and Characterization of ERBB Expressing Human Heart Progenitor Cells

TypeobservationalSponsorDouglas B. SawyerRan2015 to 2029Enrolled80ConditionsHeart Disease, Vascular Disease, Heart Failure
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Sergey RyzhovMaine Medical Center Research Institute, Scarborough, ME, United States.
Michael P RobichMaine Medical Center Research Institute, Scarborough, ME, United States; Maine Medical Center, Portland, ME, United States.
Daniel J RobertsMaine Medical Center Research Institute, Scarborough, ME, United States; Maine Medical Center, Portland, ME, United States.
Amanda J Favreau-LessardMaine Medical Center Research Institute, Scarborough, ME, United States.
Sarah M PetersonMaine Medical Center Research Institute, Scarborough, ME, United States.
Edward JachimowiczMaine Medical Center Research Institute, Scarborough, ME, United States.
Rutwik RathMaine Medical Center Research Institute, Scarborough, ME, United States.
Calvin P H VaryMaine Medical Center Research Institute, Scarborough, ME, United States.
Reed QuinnMaine Medical Center, Portland, ME, United States.
Robert S KramerMaine Medical Center, Portland, ME, United States.
Douglas B SawyerMaine Medical Center Research Institute, Scarborough, ME, United States; Maine Medical Center, Portland, ME, United States. Electronic address: DSawyer@mmc.org.
Maine Medical Center Research Institute · USMaine Medical Center · US

Funding

Translational Research Technologies CoreU54GM115516 · MAINEHEALTH · 2025 to 2025
$4.0M
The role of night shift work in metabolic disorders during and after pregnancyP20GM121301 · MAINEHEALTH · 2025 to 2025
$2.6M
Neuregulin signaling in myeloid cellsR01HL136560 · MAINEHEALTH · 2025 to 2025
$582k
NHLBI NIH HHS F32 HL136076NHLBI NIH HHS P20 HL101425NHLBI NIH HHS R01 HL136560NHLBI NIH HHS U01 HL100398NIGMS NIH HHS P20 GM121301NIGMS NIH HHS P30 GM103392NIGMS NIH HHS P30 GM106391NIGMS NIH HHS U54 GM115516
6 · The paper itself

Abstract

The adult human heart contains a subpopulation of highly proliferative cells. The role of ErbB receptors in these cells has not been studied. From human left ventricular (LV) epicardial biopsies, we isolated highly proliferative cells (eHiPC) to characterize the cell surface expression and function of ErbB receptors in the regulation of cell proliferation and phenotype. We found that human LV eHiPC express all four ErbB receptor subtypes. However, the expression of ErbB receptors varied widely among eHiPC isolated from different subjects. eHiPC with higher cell surface expression of ErbB2 reproduced the phenotype of endothelial cells and were characterized by endothelial cell-like functional properties. We also found that EGF/ErbB1 induces VEGFR2 expression, while ligands for both ErbB1 and ErbB3/4 induce expression of Tie2. The number of CD31

Indexed as

AnimalsBiomarkersBiopsyCell CountCell MembraneCell Membrane PermeabilityCell ProliferationEndothelial CellsEpidermal Growth FactorErb-b2 Receptor Tyrosine KinasesFemaleHeart VentriclesHumansLigandsMaleMiddle AgedBiomarkersEpidermal Growth FactorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesLigandsCell biologyCell differentiationMyocardiumNeuregulin

Identifiers

PMID29291395
PMCPMC5926239
OpenAlexW2778230623

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.